该信息由智通财经网提供 智通财经APP讯，药明康德(02359)发布公告，于2025年8月22日斥资2999.46万元回购A股股份32.35万 股，每股回购价格为91.35-93.92元。 ...

药明康德（603259）(02359)发布公告，于2025年8月22日斥资2999.46万元回购A股股份32.35万股，每股 回购价格为91.35-93.92元。 ...

格隆汇8月22日丨药明康德(02359.HK)发布公告，2025年8月22日耗资2999.5万元人民币回购32.35万股A 股，回购价格每股91.35-93.92元。 ...

-今日A股共有22只个股换手率超过30%； 【振幅大】 -今日A股共有10只个股振幅超过20%； -N能之光、科创信息、同惠电子等个股振幅居前； 【换手率高】 -主力资金今日净流入计算机、电子、传媒等板块，净流出医药生物、基础化工、有色金属等板块； -东方财富、中兴通讯、昆仑万维、川润股份、同花顺主力资金净流入规模居前，分别净流入19.87亿 元、16.97亿元、12.92亿元、8.89亿元、7.00亿元； -每日互动、歌尔股份、北信源、跨境通、药明康德主力资金净流出规模居前，分别净流出6.23亿元、 5.45亿元、5.09亿元、4.39亿元、4.11亿元。 (本文来自第一财经) -N能之光、南方精工、科创信息等个股换手率居前； 【主力资金】 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

Market Performance - The Shanghai Composite Index increased by 3.49% this week, while the Shenzhen Component Index rose by 4.57%, and the ChiNext Index surged by 5.85%. The CSI 300 Index saw an increase of 4.18% [1] - Among the tradable A-shares, 4,295 stocks rose, accounting for 79.29%, while 1,069 stocks declined [1] Capital Flow - The total net outflow of main funds this week was 149.116 billion yuan. The ChiNext saw a net outflow of 64.994 billion yuan, and the STAR Market had a net outflow of 7.137 billion yuan. Conversely, the CSI 300 experienced a net inflow of 9.386 billion yuan [1][2] - On August 22, the net inflow for the Shanghai and Shenzhen markets was 25.419 billion yuan, while on August 21, there was a significant outflow of 66.420 billion yuan [2] Industry Performance - In terms of industry performance, 31 out of the 38 primary industries tracked by Shenwan rose this week, with the telecommunications and electronics sectors leading with increases of 10.84% and 8.95%, respectively [3] - The telecommunications sector had the highest net inflow of main funds, totaling 6.472 billion yuan, while the food and beverage sector saw a net inflow of 1.870 billion yuan with a weekly increase of 3.29% [3][4] Individual Stock Performance - A total of 1,778 stocks experienced net inflows this week, with 295 stocks having net inflows exceeding 100 million yuan. ZTE Corporation led with a net inflow of 7.798 billion yuan and a price increase of 32.21% [5] - Conversely, 626 stocks had net outflows exceeding 100 million yuan, with Dongfang Wealth, Wolong Electric Drive, and WuXi AppTec leading in outflows of 3.935 billion yuan, 3.729 billion yuan, and 3.143 billion yuan, respectively [5]

金融界8月22日消息，上证指数高开高走，上证50等权重指数 (50等权，000050)上涨2.73%，报2309.57 点，成交额1806.45亿元。 数据统计显示，上证50等权重指数近一个月上涨4.63%，近三个月上涨7.16%，年至今上涨6.14%。 从上证50等权重指数持仓样本的行业来看，金融占比24.45%、工业占比17.45%、信息技术占比 14.91%、原材料占比9.06%、能源占比7.50%、可选消费占比5.67%、主要消费占比5.54%、通信服务占 比5.41%、医药卫生占比4.75%、公用事业占比3.47%、房地产占比1.78%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过10%。样本调整设置缓冲区，排名在40名之前的候选新样本优 先进入，排名在60名之前的老样本优先保留。特殊情况下将对指数进行临时调整。当样本退市时，将其 从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，上证50等权重指数十大权重分别为：寒武纪（3.09%）、洛阳钼业（2.7%）、药明 ...

Core Insights - The medical services sector experienced a slight increase of 0.18% on August 22, with a net outflow of 494 million yuan in principal funds [1] - Among the constituent stocks, 21 rose while 22 fell, indicating mixed performance within the sector [1] Fund Flow Analysis - The top net outflow stocks included WuXi AppTec with 193 million yuan, Sanbo Brain Science with 162 million yuan, and Kailaiying with approximately 71.53 million yuan [1] - Other notable outflows were observed in Zhaoyan New Drug (52.94 million yuan) and Innovation Medical (44.23 million yuan) [1] Stock Performance - Haocen Medical saw a significant increase of 9.92% with a net inflow of 116 million yuan, representing 19.82% of its market [1] - Baihua Medicine and Dian Diagnostics also reported gains of 1.51% and 2.41%, with net inflows of 414.83 thousand yuan and 393.43 thousand yuan respectively [1] - Conversely, Chengda Pharmaceutical and Guangzheng Eye Care experienced declines of 3.38% and 2.09% respectively, with net outflows of 2149.15 thousand yuan and 1199.08 thousand yuan [1]

Core Viewpoint - Hansoh Pharmaceutical plans to raise HKD 3.9 billion through a placement, marking its third refinancing since its listing, with its stock price currently at approximately 80% of its historical high [2] Group 1: Financing Activities - Since the beginning of 2025, over 20 innovative pharmaceutical companies listed in Hong Kong have engaged in refinancing, significantly surpassing the same period last year, with total refinancing exceeding HKD 34 billion [2][4] - WuXi AppTec raised nearly HKD 7.7 billion through a share placement, making it the highest fundraising company in this round of refinancing [5] - Innovent Biologics raised approximately HKD 4.3 billion through the placement of 55 million new shares, with 90% of the funds allocated for global R&D and facility layout [5] Group 2: Stock Performance and Market Trends - The stock prices of many innovative pharmaceutical companies have doubled since the beginning of the year, indicating a market recovery [2] - Innovent Biologics' stock price has increased over 2.5 times since the start of the year, reflecting strong market interest [10] Group 3: Shareholder Actions - Some founders and major shareholders are taking the opportunity to reduce their holdings and cash out, despite the ongoing fundraising activities [4][10] - Notable reductions include Temasek's divestment of over HKD 2.4 billion from Innovent Biologics and significant sales by other major shareholders in various companies [10][11] Group 4: Alternative Financing Methods - Several companies are utilizing "old-for-new" financing methods, where founders sell their old shares to new investors and use the cash to subscribe to new shares, making it more attractive for investors [7][8] - Companies like Aisheng Pharmaceutical and others have successfully raised funds through this method, indicating a trend in the market [8]

本报记者 张文湘 贺王娟 A股上市公司半年报正密集披露，现金分红成为投资者关注的焦点之一。Wind资讯数据显示，截至8月 21日记者发稿，A股上市公司中共有171家公司（包括13家已落地实施的企业）披露2025年半年度分红 预案，涉及非银金融、医药生物、计算机、汽车、教育、通信等行业，拟总派发1245.84亿元。 苏商银行特约研究员武泽伟对《证券日报》记者表示，上市公司中期分红呈现出参与主体扩大、分红规 模增长及股息支付率稳步提升的特征。 从金额来看，分红金额超10亿元的公司有15家。其中，超百亿元的上市公司有2家，分别是中国移动有 限公司拟分红超540亿元，中国电信股份有限公司拟派发165.81亿元。 此外，有7家上市公司分红金额超20亿元，分别为：北京东方雨虹防水技术股份有限公司拟派现22.1亿 元、河南双汇投资发展股份有限公司拟派现22.5亿元、福耀玻璃工业集团股份有限公司拟派现23.5亿 元、中国联合网络通信股份有限公司拟派现34.8亿元、杭州海康威视数字技术股份有限公司拟派现36.9 亿元、宁德时代新能源科技股份有限公司派现超40亿元、牧原食品股份有限公司（以下简称"牧原股 份"）拟派现50.02亿 ...